Table 2.
Summary of opioid and laxative use.
| Parameter | n (%) |
|---|---|
| Daily dose of opioids * | |
| ≤19 mg | 106 (36.9%) |
| 20–49 mg | 112 (39.0%) |
| 50–99 mg | 35 (12.2%) |
| ≥100 mg | 34 (11.8%) |
| Regular use of opioids * | |
| Oxycodone | 165 (57.5%) |
| Morphine | 49 (17.1%) |
| Fentanyl | 42 (14.6%) |
| Hydromorphone | 21 (7.3%) |
| Others | 10 (3.5%) |
| Days from opioid initiation to starting naldemedine † | |
| ≤3 days | 68 (23.0%) |
| 4–7 days | 55 (18.6%) |
| 8–14 days | 53 (17.9%) |
| 15–29 days | 46 (15.5%) |
| 30–99 days | 43 (14.5%) |
| ≥100 days | 30 (10.1%) |
| Coadministration of laxatives ‡ | |
| Magnesium oxide | 190 (81.5%) |
| Sennoside | 81 (34.8%) |
| Bisacodyl | 31 (13.3%) |
| Lubiprostone | 26 (11.2%) |
| Sodium picosulfate hydrate | 23 (9.9%) |
| Others | 20 (8.6%) |
* Oral morphine equivalent to regular opioids. Nine patients who did not use regular opioids were excluded when calculating the percentages. † The number of days of use in one patient who had started opioids at another hospital could not be determined. ‡ Percentages were calculated for 233 patients who were using laxatives concomitantly.